View Item 

Show simple item record

Factors Influencing Patient Decision‐Making Concerning Treatment Escalation in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
dc.contributor.authorHughes, Michael
dc.contributor.authorHuang, Suiyuan
dc.contributor.authorPauling, John D.
dc.contributor.authorSabbagh, Maya
dc.contributor.authorKhanna, Dinesh
dc.date.accessioned2022-01-06T15:50:22Z
dc.date.available2023-01-06 10:50:21en
dc.date.available2022-01-06T15:50:22Z
dc.date.issued2021-12
dc.identifier.citationHughes, Michael; Huang, Suiyuan; Pauling, John D.; Sabbagh, Maya; Khanna, Dinesh (2021). "Factors Influencing Patient Decision‐Making Concerning Treatment Escalation in Raynaud’s Phenomenon Secondary to Systemic Sclerosis." Arthritis Care & Research (12): 1845-1852.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/171202
dc.publisherWiley Periodicals, Inc.
dc.titleFactors Influencing Patient Decision‐Making Concerning Treatment Escalation in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171202/1/acr24710.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171202/2/acr24710_am.pdf
dc.identifier.doi10.1002/acr.24710
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceHughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, et al. Multicenter qualitative study exploring the patient experience of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 2020; 72: 723 – 33.
dc.identifier.citedreferenceLajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulm Circ 2017; 7: 312 – 25.
dc.identifier.citedreferenceMurphy SL, Lescoat A, Alore M, Hughes M, Pauling JD, Sabbagh M, et al. How do patients define Raynaud’s phenomenon? Differences between primary and secondary disease. Clin Rheumatol 2021; 40: 1611 – 6.
dc.identifier.citedreferencePauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, et al. Multinational qualitative research study exploring the patient experience of Raynaud’s phenomenon in systemic sclerosis. Arthritis Care Res (Hoboken) 2018; 70: 1373 – 84.
dc.identifier.citedreferenceDaniels J, Pauling JD, Eccleston C. Behaviour change interventions for the management of Raynaud’s phenomenon: a systematic literature review. BMJ Open 2018; 8: e024528.
dc.identifier.citedreferenceMerkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002; 46: 2410 – 20.
dc.identifier.citedreferenceKhanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud’s condition score in patients with Raynaud’s phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis 2010; 69: 588 – 91.
dc.identifier.citedreferencePauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, et al. Patient‐reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis: a SCTC vascular working group report. J Scleroderma Relat Disord 2018; 3: 249 – 52.
dc.identifier.citedreferencePauling JD, Saketkoo LA, Matucci‐Cerinic M, Ingegnoli F, Khanna D. The patient experience of Raynaud’s phenomenon in systemic sclerosis. Rheumatology (Oxford) 2019; 58: 18 – 26.
dc.identifier.citedreferenceHughes M, Pauling JD. Exploring the patient experience of digital ulcers in systemic sclerosis. Semin Arthritis Rheum 2019; 48: 888 – 94.
dc.identifier.citedreferencePauling JD, Reilly E, Smith T, Frech TM. Factors influencing Raynaud’s condition score diary outcomes in systemic sclerosis. J Rheumatol 2019; 46: 1326 – 34.
dc.identifier.citedreferenceHughes M. Effect of season on internet searches for information on Raynaud phenomenon. J Rheumatol 2019; 46: 1543 – 4.
dc.identifier.citedreferenceDevgire V, Martin AF, McKenzie L, Sandler RD, Hughes M. A systematic review of internet‐based information for individuals with Raynaud’s phenomenon and patients with systemic sclerosis. Clin Rheumatol 2020; 39: 2363 – 7.
dc.identifier.citedreferenceSpierings J, van Rhijn‐Brouwer FC, de Bresser CJ, Mosterman PT, Pieterse AH, Vonk MC, et al. Treatment decision‐making in diffuse cutaneous systemic sclerosis: a patient’s perspective. Rheumatology (Oxford) 2020; 59: 2052 – 61.
dc.identifier.citedreferenceAvouac J, Airò P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290 – 8.
dc.identifier.citedreferenceVandecasteele E, Melsens K, Thevissen K, De Pauw M, Deschepper E, Decuman S, et al. Prevalence and incidence of pulmonary arterial hypertension: 10‐year follow‐up of an unselected systemic sclerosis cohort. J Scleroderma Relat Disord 2017; 2: 196 – 202.
dc.identifier.citedreferenceHughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology (Oxford) 2017; 56: 14 – 25.
dc.identifier.citedreferenceMorrisroe K, Stevens W, Sahhar J, Ngian GS, Ferdowsi N, Hill CL, et al. Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. Arthritis Res Ther 2019; 21: 299.
dc.identifier.citedreferenceMihai C, Distler O, Gheorghiu AM, Constantin P, Dobrota R, Jordan S, et al. Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology (Oxford) 2020; 59: 2016 – 23.
dc.identifier.citedreferenceBassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 2011; 50: 762 – 7.
dc.identifier.citedreferenceHughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL. Prediction and impact of attacks of Raynaud’s phenomenon, as judged by patient perception. Rheumatology (Oxford) 2015; 54: 1443 – 7.
dc.identifier.citedreferenceMatucci‐Cerinic M, Kahaleh B, Wigley FM. Evidence that systemic sclerosis is a vascular disease [review]. Arthritis Rheum 2013; 65: 1953 – 62.
dc.identifier.citedreferenceHughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci‐Cerinic M. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 2020; 16: 208 – 21.
dc.identifier.citedreferenceHughes M, Khanna DK, Pauling JD. Drug Initiation and escalation strategies of vasodilator therapies for Raynaud’s phenomenon: can we treat to target? Rheumatology (Oxford) 2020; 59: 464 – 6.
dc.identifier.citedreferenceMeier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012; 71: 1355 – 60.
dc.identifier.citedreferenceHughes M, Ong VH, Anderson ME, Hall F, Moinzadeh P, Griffiths B, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology (Oxford) 2015; 54: 2015 – 24.
dc.identifier.citedreferenceDenton C, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford) 2016; 55: 1906 – 10.
dc.identifier.citedreferenceFernández‐Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 2018; 70: 1820 – 8.
dc.identifier.citedreferenceRirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, et al. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev 2017; 12: CD000467.
dc.identifier.citedreferenceAtar D, Birkeland KI, Uhlig T. “Treat to target”: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. Ann Rheum Dis 2010; 69: 629 – 30.
dc.identifier.citedreferenceSolomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? [review]. Arthritis Rheumatol 2014; 66: 775 – 82.
dc.identifier.citedreferenceVan Vollenhoven R. Treat‐to‐target in rheumatoid arthritis: are we there yet? Nat Rev Rheumatol 2019; 15: 180 – 6.
dc.identifier.citedreferenceGaliè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834 – 44.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr24710.pdf
Size:
365.9KB
Format:
PDF
View/Open
Name:
acr24710_am.pdf
Size:
389.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.